Q0F (Q0F) Fair Value & Analysis
Healthcare · SG · Market cap 25.1B SGD
Fair value as of: Jul 4, 2026
From 24 valuation models · updated today
Share price −1.4% over the past month.
Price vs Fair Value (12 months)
12‑month range 1.95 SGD – 3.05 SGD · fair‑value band 0.9100 SGD – 1.64 SGD · the 2.76 SGD price screens above the 1.28 SGD fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Q0F (Q0F) currently trades at 2.76 SGD, while our model-based Fair Value estimate is 1.28 SGD — implying the stock looks roughly 53.6% overvalued today. We read business quality at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Q0F generated revenue of 26.0B SGD at a net margin of 8.1%. Revenue grew 4.1% year over year. It earns a return on equity of 7.9%. Net debt stands at 11.8B SGD. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
IHH Healthcare Berhad, an investment holding company, offers healthcare services in Malaysia, Singapore, Turkey, India, China, Japan, Europe, and internationally. It provides primary care services, such as outpatient treatment, check-ups, vaccinations, preventive care, and patient education services. The company also offers secondary care facilities, including medical emergencies and acute treatment, as well as specialist consultation, diagnostics, and lab services; tertiary care services comprising specialist consultative care, advanced treatment, complex surgery, and inpatient care services; and quaternary care services, such as organ transplants, neurosurgery, cardiac surgery, and reconstructive plastic surgery. In addition, it provides ancillary services, including diagnostics, laboratory testing, radiology, physiotherapy, and integrated rehabilitation and advanced molecular diagnostics services. Further, the company offers medical education; train and develop nurses, doctors, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Q0F reported revenue of 25.7B SGD in FY2025 versus 17.1B SGD in FY2021, a compound +10.7%/yr. Reported net income was 2.1B SGD in FY2025, compounding +3.1%/yr from FY2021.
Is Q0F fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$97.60 | R$115.75 | +19% |
| Fresenius SE FSNUY | $11.47 | $8.55 | -25% |
| 5225 5225 | 8.71 MYR | 4.87 MYR | -44% |
| IHHHF IHHHF | $1.71 | $1.17 | -32% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.50 | R$46.04 | +42% |
| Tenet Healthcare Corporation THC | $164.77 | $280.85 | +70% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Q0F (Q0F) undervalued?
What is the fair value of Q0F?
What is the quality score of Q0F?
What is the revenue of Q0F (Q0F)?
What is the net profit margin of Q0F?
Does Q0F pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.